SK287481B6 - Farmaceutická kompozícia s terapeutickou synergiou pri liečení neoplastického ochorenia obsahujúca docetaxel a flavopiridol - Google Patents

Farmaceutická kompozícia s terapeutickou synergiou pri liečení neoplastického ochorenia obsahujúca docetaxel a flavopiridol Download PDF

Info

Publication number
SK287481B6
SK287481B6 SK1169-2003A SK11692003A SK287481B6 SK 287481 B6 SK287481 B6 SK 287481B6 SK 11692003 A SK11692003 A SK 11692003A SK 287481 B6 SK287481 B6 SK 287481B6
Authority
SK
Slovakia
Prior art keywords
flavopiridol
docetaxel
days
pharmaceutical composition
tumor
Prior art date
Application number
SK1169-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK11692003A3 (sk
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of SK11692003A3 publication Critical patent/SK11692003A3/sk
Publication of SK287481B6 publication Critical patent/SK287481B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1169-2003A 2001-03-23 2002-03-22 Farmaceutická kompozícia s terapeutickou synergiou pri liečení neoplastického ochorenia obsahujúca docetaxel a flavopiridol SK287481B6 (sk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04
PCT/EP2002/004083 WO2002076484A2 (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor

Publications (2)

Publication Number Publication Date
SK11692003A3 SK11692003A3 (sk) 2004-03-02
SK287481B6 true SK287481B6 (sk) 2010-11-08

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1169-2003A SK287481B6 (sk) 2001-03-23 2002-03-22 Farmaceutická kompozícia s terapeutickou synergiou pri liečení neoplastického ochorenia obsahujúca docetaxel a flavopiridol

Country Status (33)

Country Link
US (2) US20020182204A1 (es)
EP (1) EP1372652B1 (es)
JP (1) JP2004521140A (es)
KR (1) KR100879712B1 (es)
CN (1) CN1498107A (es)
AR (1) AR034222A1 (es)
AT (1) ATE395917T1 (es)
AU (1) AU2002312815B2 (es)
BR (1) BR0208221A (es)
CA (1) CA2441441C (es)
CY (1) CY1110449T1 (es)
CZ (1) CZ301423B6 (es)
DE (1) DE60226710D1 (es)
DK (1) DK1372652T3 (es)
EA (1) EA007815B1 (es)
ES (1) ES2305253T3 (es)
HR (1) HRPK20030766B3 (es)
HU (1) HU229258B1 (es)
IL (2) IL158058A0 (es)
ME (1) MEP16408A (es)
MX (1) MXPA03007743A (es)
NO (1) NO332441B1 (es)
NZ (1) NZ527655A (es)
PE (1) PE20020907A1 (es)
PL (1) PL206118B1 (es)
PT (1) PT1372652E (es)
RS (1) RS50681B (es)
SI (1) SI1372652T1 (es)
SK (1) SK287481B6 (es)
TW (1) TWI355935B (es)
UY (1) UY27220A1 (es)
WO (1) WO2002076484A2 (es)
ZA (1) ZA200307381B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075943A2 (en) * 2002-03-06 2003-09-18 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
WO2004035034A2 (en) * 2002-10-16 2004-04-29 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
MXPA05004917A (es) * 2002-11-06 2005-08-18 Cyclacel Ltd Combinacion que comprende docetaxel y un inhibidor cdk.
WO2007090794A1 (en) * 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
WO2012066508A1 (en) * 2010-11-19 2012-05-24 Piramal Life Sciences Limited Pharmaceutical combination of paclitaxel and a cdk inhibitor
PL2694056T3 (pl) * 2011-04-01 2020-03-31 Astrazeneca Ab Leczenie terapeutyczne
EP2785349B2 (en) 2011-11-30 2022-11-09 Astrazeneca AB Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
CA2246734A1 (en) * 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers

Also Published As

Publication number Publication date
EA007815B1 (ru) 2007-02-27
CZ20032551A3 (en) 2004-07-14
US20060128640A1 (en) 2006-06-15
SK11692003A3 (sk) 2004-03-02
HRP20030766A2 (en) 2005-06-30
EA200301053A1 (ru) 2004-02-26
HUP0303589A2 (hu) 2004-03-01
HUP0303589A3 (en) 2007-05-02
NO332441B1 (no) 2012-09-17
AR034222A1 (es) 2004-02-04
SI1372652T1 (sl) 2008-10-31
KR20030086318A (ko) 2003-11-07
DK1372652T3 (da) 2008-09-22
CZ301423B6 (cs) 2010-02-24
CY1110449T1 (el) 2015-04-29
ATE395917T1 (de) 2008-06-15
PE20020907A1 (es) 2002-12-19
IL158058A0 (en) 2004-03-28
EP1372652B1 (en) 2008-05-21
ZA200307381B (en) 2005-03-30
WO2002076484A3 (en) 2003-01-03
AU2002312815B2 (en) 2006-08-24
NO20034124L (no) 2003-09-16
EP1372652A2 (en) 2004-01-02
MEP16408A (en) 2010-10-10
MXPA03007743A (es) 2004-11-12
PL206118B1 (pl) 2010-07-30
BR0208221A (pt) 2004-03-02
PL367702A1 (en) 2005-03-07
US20020182204A1 (en) 2002-12-05
CA2441441A1 (en) 2002-10-03
CN1498107A (zh) 2004-05-19
KR100879712B1 (ko) 2009-01-22
TWI355935B (en) 2012-01-11
ES2305253T3 (es) 2008-11-01
UY27220A1 (es) 2002-09-30
DE60226710D1 (de) 2008-07-03
WO2002076484A2 (en) 2002-10-03
YU69503A (sh) 2006-08-17
NZ527655A (en) 2006-03-31
HRPK20030766B3 (en) 2006-11-30
IL158058A (en) 2010-02-17
NO20034124D0 (no) 2003-09-16
JP2004521140A (ja) 2004-07-15
PT1372652E (pt) 2008-07-24
CA2441441C (en) 2009-05-26
RS50681B (sr) 2010-06-30
HU229258B1 (en) 2013-10-28

Similar Documents

Publication Publication Date Title
Flatters et al. Ethosuximide reverses paclitaxel-and vincristine-induced painful peripheral neuropathy
Fauzee et al. Taxanes: promising anti-cancer drugs
US20060128640A1 (en) Combination of a taxane and a cyclin-dependent kinase
Deep et al. Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review
AU2009215329B2 (en) Combination comprising paclitaxel for treating ovarian cancer
JP2009536956A (ja) 抗癌治療法
Sharma Synthetic and natural compounds as anti-cancer agents-a review
Kim et al. Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells
AU2002312815A1 (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
Kudelka et al. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix
Schmidt Dose-dense chemotherapy in metastatic breast cancer: shortening the time interval for a better therapeutic index
Georgoulias Docetaxel (taxotere) in the treatment of non-small cell lung cancer
Cividalli et al. Enhancement of radiation response by paclitaxel in mice according to different treatment schedules
CA2525277A1 (en) Method for augmenting the antitumor activity of anti-cancer agents
CN110740751A (zh) 用于治疗肺癌的结合物
Kim et al. Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer
Green et al. Radiation and chemotherapy for patients with stage III non-small cell lung cancer
Seibel et al. New microtubular agents in pediatric oncology
Mir et al. Targeted Therapies in Combination with Metronomic Chemotherapy
WO2009104152A1 (en) Combination treatment for ovarian cancer
Samimi et al. Paclitaxel-Induced Peripheral Neuropathy Using NCI-CTCin Isfahan, Iran: Paclitaxel-induced peripheral neuropathy
MXPA06010921A (es) Terapias de combinacion con epotilonas y carboplatin

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20140322